Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

miRNA related to treatment of chronic stable angina pectoris and application of miRNA

A stable, angina pectoris technology, applied in the field of circulating miRNA, to achieve the effect of improving the current treatment status

Active Publication Date: 2020-05-29
SHANDONG DANHONG PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, although many animal experiments have proved that the method is feasible, there is no treatment plan specifically targeting human mi-RNA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • miRNA related to treatment of chronic stable angina pectoris and application of miRNA
  • miRNA related to treatment of chronic stable angina pectoris and application of miRNA
  • miRNA related to treatment of chronic stable angina pectoris and application of miRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038]Example 1 Acquire new miRNAs

[0039] In this example, Illumina deep sequencing technology was used to perform high-throughput sequencing of all miRNAs in patients with chronic stable angina treated with Danhong injection for 14 days, and new miRNAs related to the treatment of chronic stable angina were discovered in combination with bioinformatics analysis sequence.

[0040] (1) Source and collection of circulating mi-RNA

[0041] All patients were given a standardized medical treatment plan for chronic stable angina pectoris, which was formulated with reference to the "2007 Guidelines for the Diagnosis and Treatment of Chronic Stable Angina Pectoris in China", including:

[0042] 1. Anti-platelet aggregation drugs: aspirin 75-100mg Qd, patients who cannot tolerate aspirin, can switch to clopidogrel as an alternative treatment; patients with previous PCI surgery history need to take the above two drugs at the same time;

[0043] 2. Lipid-lowering drugs: statin lipid-l...

Embodiment 2

[0072] Example 2 Positive rate and response rate of new miRNA in diseased population

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides miRNA related to the treatment of chronic stable angina pectoris. The miRNA comprises nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. The miRNA sequences improve an existing miRNA database, helps to further understand target sites for drug treatment of chronic stable angina pectoris, can be used for the development of the drugs targeting the target sites of chronic stable angina of the type of miRNA, and has important application value in the field of treatment of angina pectoris especially for chronic stable angina pectoris.

Description

technical field [0001] The invention belongs to the field of medical molecular biology, in particular, the invention relates to a newly discovered circulating miRNA related to the treatment of chronic stable angina pectoris. Background technique [0002] Coronary heart disease has become a major cause of death in humans (Mozaffarian D et al., Circulation 2015; 131:e29-322). Chronic stable angina is the most common type of coronary heart disease, and nearly 50% of patients with coronary heart disease have chronic stable angina. [0003] miRNA (microRNA) is a class of single-stranded, non-coding small molecule RNA (18-22nt) that is highly conserved in evolution, and negatively regulates the expression of target genes at the post-transcriptional level. Studies have shown that miRNA is involved in the regulation of many physiological and pathological processes in the body, and is closely related to the onset or prognosis of cardiovascular diseases, diabetes, tumors and other di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12N15/113A61K45/00A61P9/10
CPCC12Q1/6883A61K45/00A61P9/10C12Q2600/158C12Q2600/178
Inventor 王忠刘骏于亚南王益民南景一郭剑
Owner SHANDONG DANHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com